

# Neuroendocrine Tumors Therapeutics Market Size, Trends, Analysis, and Outlook By Product (Somatostatin Analogs (SSAs), Targeted Therapy, Chemotherapy, Others), By Indication (Lungs, Pancreas, Gastrointestinal, Others), By End-User (Hospitals, Clinics, Others), by Region, Country, Segment, and Companies, 2024-2030

<https://marketpublishers.com/r/N6FBE1064A80EN.html>

Date: March 2024

Pages: 190

Price: US\$ 3,980.00 (Single User License)

ID: N6FBE1064A80EN

## Abstracts

The global Neuroendocrine Tumors Therapeutics market size is poised to register 11.64% growth (CAGR) from 2024 to 2030, presenting significant growth prospects for companies operating in the industry. The industry study analyzes the global Neuroendocrine Tumors Therapeutics market By Product (Somatostatin Analogs (SSAs), Targeted Therapy, Chemotherapy, Others), By Indication (Lungs, Pancreas, Gastrointestinal, Others), By End-User (Hospitals, Clinics, Others).

The future of neuroendocrine tumors (NETs) therapeutics is shaped by advancements in oncology, molecular imaging, and precision medicine aimed at improving outcomes for patients with rare and heterogeneous malignancies arising from neuroendocrine cells in various organs, such as the pancreas, gastrointestinal tract, and lung. Key trends include the development of targeted therapies, peptide receptor radionuclide therapy (PRRT), and somatostatin analogs that selectively target overexpressed receptors or signaling pathways in NET cells, thereby inducing tumor regression, controlling hormone secretion, and prolonging progression-free survival in advanced-stage NET patients. Additionally, there is a growing emphasis on the integration of multimodal treatment approaches, including surgery, locoregional therapies, and systemic treatments, in multidisciplinary care models that optimize disease control, symptom management, and quality of life outcomes in NET patients across different

disease stages and tumor grades. Moreover, advancements in molecular imaging agents, radiopharmaceuticals, and tumor biomarkers enable accurate diagnosis, staging, and treatment response assessment in NETs, driving continuous innovation and adoption of therapeutics in oncology practice and clinical trials..

## Neuroendocrine Tumors Therapeutics Market Drivers, Trends, Opportunities, and Growth Opportunities

This comprehensive study discusses the latest trends and the most pressing challenges for industry players and investors. The Neuroendocrine Tumors Therapeutics market research analyses the global market trends, key drivers, challenges, and opportunities in the industry. In addition, the latest Future of Neuroendocrine Tumors Therapeutics survey report provides the market size outlook across types, applications, and other segments across the world and regions. It provides data-driven insights and actionable recommendations for companies in the Neuroendocrine Tumors Therapeutics industry.

## Key market trends defining the global Neuroendocrine Tumors Therapeutics demand in 2024 and Beyond

The industry continues to remain an attractive hub for opportunities for both domestic and global vendors. As the market evolves, factors such as emerging market dynamics, demand from end-user sectors, a growing patient base, changes in consumption patterns, and widening distribution channels continue to play a major role.

## Neuroendocrine Tumors Therapeutics Market Segmentation- Industry Share, Market Size, and Outlook to 2030

The Neuroendocrine Tumors Therapeutics industry comprises a wide range of segments and sub-segments. The rising demand for these product types and applications is supporting companies to increase their investment levels across niche segments. Accordingly, leading companies plan to generate a large share of their future revenue growth from expansion into these niche segments. The report presents the market size outlook across segments to support Neuroendocrine Tumors Therapeutics companies scaling up production in these sub-segments with a focus on expanding into emerging countries.

## Key strategies adopted by companies within the Neuroendocrine Tumors Therapeutics industry

Leading Neuroendocrine Tumors Therapeutics companies are boosting investments to capitalize on untapped potential and future possibilities across niche market segments and surging demand conditions in key regions. Further, companies are leveraging advanced technologies to unlock opportunities and achieve operational excellence. The report provides key strategies opted for by the top 10 Neuroendocrine Tumors Therapeutics companies.

### Neuroendocrine Tumors Therapeutics Market Study- Strategic Analysis Review

The Neuroendocrine Tumors Therapeutics market research report dives deep into the qualitative factors shaping the market, empowering you to make informed decisions-

**Industry Dynamics:** Porter's Five Forces analysis to understand bargaining power, competitive rivalry, and threats that impact long-term strategy formulation.

**Strategic Insights:** Provides valuable perspectives on key players and their approaches based on comprehensive strategy analysis.

**Internal Strengths and Weaknesses:** Develop targeted strategies to leverage strengths, address weaknesses, and capitalize on market opportunities.

**Future Possibilities:** Prepare for diverse outcomes with in-depth scenario analysis. Explore potential market disruptions, technology advancements, and economic changes.

### Neuroendocrine Tumors Therapeutics Market Size Outlook- Historic and Forecast Revenue in Three Cases

The Neuroendocrine Tumors Therapeutics industry report provides a detailed analysis and outlook of revenue generated by companies from 2018 to 2023. Further, with actual data for 2023, the report forecasts the market size outlook from 2024 to 2030 in three case scenarios- low case, reference case, and high case scenarios.

### Neuroendocrine Tumors Therapeutics Country Analysis and Revenue Outlook to 2030

The report analyses 22 countries worldwide including the key driving forces and market size outlook from 2021 to 2030. In addition, region analysis across Asia Pacific, Europe,

the Middle East, Africa, North America, and South America is included in the study. For each of the six regions, the market size outlook by segments is forecast for 2030.

**North America Neuroendocrine Tumors Therapeutics Market Size Outlook- Companies plan for focused investments in a changing environment**

The US continues to remain the market leader in North America, driven by a large consumer base, the presence of well-established providers, and a strong end-user industry demand. Leading companies focus on new product launches in the changing environment. The US economy is expected to grow in 2024 (around 2.2% growth in 2024), potentially driving demand for various Neuroendocrine Tumors Therapeutics market segments. Similarly, Strong end-user demand is encouraging Canadian Neuroendocrine Tumors Therapeutics companies to invest in niche segments. Further, as Mexico continues to strengthen its trade relations and invest in technological advancements, the Mexico Neuroendocrine Tumors Therapeutics market is expected to experience significant expansion, offering lucrative opportunities for both domestic and international stakeholders.

**Europe Neuroendocrine Tumors Therapeutics Market Size Outlook-Companies investing in assessing consumers, categories, competitors, and capabilities**

The German industry remains the major market for companies in the European Neuroendocrine Tumors Therapeutics industry with consumers in Germany, France, the UK, Spain, Italy, and others anticipated to register a steady demand throughout the forecast period, driving the overall market prospects. In addition, the proactive approach of businesses in identifying and leveraging new growth prospects positions the European Neuroendocrine Tumors Therapeutics market for an upward trajectory, fostering both domestic and international interest. Leading brands operating in the industry are emphasizing effective marketing strategies, innovative product offerings, and a keen understanding of consumer preferences.

**Asia Pacific Neuroendocrine Tumors Therapeutics Market Size Outlook- an attractive hub for opportunities for both local and global companies**

The increasing prevalence of indications, robust healthcare expenditure, and increasing investments in healthcare infrastructure drive the demand for Neuroendocrine Tumors Therapeutics in Asia Pacific. In particular, China, India, and South East Asian Neuroendocrine Tumors Therapeutics markets present a compelling outlook for 2030, acting as a magnet for both domestic and multinational manufacturers seeking growth

opportunities. Similarly, with a burgeoning population and a rising middle class, India offers a vast consumer market. Japanese and Korean companies are quickly aligning their strategies to navigate changes, explore new markets, and enhance their competitive edge. Our report utilizes in-depth interviews with industry experts and comprehensive data analysis to provide a comprehensive outlook of 6 major markets in the region.

### Latin America Neuroendocrine Tumors Therapeutics Market Size Outlook- Continued urbanization and rising income levels

Rising income levels contribute to greater purchasing power among consumers, spurring consumption and creating opportunities for market expansion. Continued urbanization and rising income levels are expected to sustainably drive consumption growth in the medium to long term.

### Middle East and Africa Neuroendocrine Tumors Therapeutics Market Size Outlook- continues its upward trajectory across segments

Robust demand from Middle Eastern countries including Saudi Arabia, the UAE, Qatar, Kuwait, and other GCC countries supports the overall Middle East Neuroendocrine Tumors Therapeutics market potential. Fueled by increasing healthcare expenditure of individuals, growing population, and high prevalence across a few markets drives the demand for Neuroendocrine Tumors Therapeutics.

### Neuroendocrine Tumors Therapeutics Market Company Profiles

The global Neuroendocrine Tumors Therapeutics market is characterized by intense competitive conditions with leading companies opting for aggressive marketing to gain market shares. The report presents business descriptions, SWOT analysis, growth strategies, and financial profiles. Leading companies included in the study are AVEO Pharmaceuticals Inc, Boehringer Ingelheim International GmbH, Bristol-Myers Squibb, Eli Lilly & Company, F. Hoffmann-La Roche Ltd, Hutchison MediPharma Ltd, Ipsen, Jubilant Life Sciences Ltd, Lantheus Holdings Inc, Novartis AG, Pfizer Inc, Tarveda Therapeutics.

### Recent Neuroendocrine Tumors Therapeutics Market Developments

The global Neuroendocrine Tumors Therapeutics market study presents recent market news and developments including new product launches, mergers, acquisitions,

expansions, product approvals, and other updates in the industry.

Neuroendocrine Tumors Therapeutics Market Report Scope

Parameters: Revenue, Volume Price

Study Period: 2023 (Base Year); 2018- 2023 (Historic Period); 2024- 2030 (Forecast Period)

Currency: USD; (Upon request, can be provided in Euro, JPY, GBP, and other Local Currency)

Qualitative Analysis

Pricing Analysis

Value Chain Analysis

SWOT Profile

Market Dynamics- Trends, Drivers, Challenges

Porter's Five Forces Analysis

Macroeconomic Impact Analysis

Case Scenarios- Low, Base, High

Market Segmentation:

By Type

Stationary 3D and 4D Ultrasound Devices

Portable 3D and 4D Ultrasound Devices

By Display

Color Ultrasound

B/W Ultrasound

By Portability

Trolley or Cart-Based Ultrasound Systems

Compact/Handheld Ultrasound Systems

Point-of-Pare (PoC) Ultrasound Systems

By Application

Radiology or General Imaging

Obstetrics or Gynecology

Cardiology

Urology

Vascular

Orthopedic and Musculoskeletal

Pain Management

Others

By End-User

Hospitals

Surgical Centers and Diagnostic Centers

Maternity Centers

Ambulatory Care Centers

Research and Academia

Others

Geographical Segmentation:

North America (3 markets)

Europe (6 markets)

Asia Pacific (6 markets)

Latin America (3 markets)

Middle East Africa (5 markets)

Companies

AVEO Pharmaceuticals Inc

Boehringer Ingelheim International GmbH

Bristol-Myers Squibb

Eli Lilly & Company

F. Hoffmann-La Roche Ltd

Hutchison MediPharma Ltd

Ipsen

Jubilant Life Sciences Ltd

Lantheus Holdings Inc

Novartis AG



Pfizer Inc

Tarveda Therapeutics

Formats Available: Excel, PDF, and PPT

## Contents

### **1. EXECUTIVE SUMMARY**

- 1.1 Neuroendocrine Tumors Therapeutics Market Overview and Key Findings, 2024
- 1.2 Neuroendocrine Tumors Therapeutics Market Size and Growth Outlook, 2021- 2030
- 1.3 Neuroendocrine Tumors Therapeutics Market Growth Opportunities to 2030
- 1.4 Key Neuroendocrine Tumors Therapeutics Market Trends and Challenges
  - 1.4.1 Neuroendocrine Tumors Therapeutics Market Drivers and Trends
  - 1.4.2 Neuroendocrine Tumors Therapeutics Market Challenges
- 1.5 Competitive Landscape and Key Players
- 1.6 Competitive Analysis- Growth Strategies Adopted by Leading Neuroendocrine Tumors Therapeutics Companies

### **2. NEUROENDOCRINE TUMORS THERAPEUTICS MARKET SIZE OUTLOOK TO 2030**

- 2.1 Neuroendocrine Tumors Therapeutics Market Size Outlook, USD Million, 2021-2030
- 2.2 Neuroendocrine Tumors Therapeutics Incremental Market Growth Outlook, %, 2021- 2030
- 2.3 Segment Snapshot, 2024

### **3. NEUROENDOCRINE TUMORS THERAPEUTICS MARKET- STRATEGIC ANALYSIS REVIEW**

- 3.1 Porter's Five Forces Analysis
  - \* Threat of New Entrants
  - \* Threat of Substitutes
  - \* Intensity of Competitive Rivalry
  - \* Bargaining Power of Buyers
  - \* Bargaining Power of Suppliers
- 3.2 Value Chain Analysis
- 3.3 SWOT Analysis

### **4. NEUROENDOCRINE TUMORS THERAPEUTICS MARKET SEGMENTATION ANALYSIS AND OUTLOOK**

- 4.1 Market Segmentation and Scope

## 4.2 Market Breakdown by Type, Application, and Other Segments, 2021-2030

### By Type

Stationary 3D and 4D Ultrasound Devices

Portable 3D and 4D Ultrasound Devices

### By Display

Color Ultrasound

B/W Ultrasound

### By Portability

Trolley or Cart-Based Ultrasound Systems

Compact/Handheld Ultrasound Systems

Point-of-Pare (PoC) Ultrasound Systems

### By Application

Radiology or General Imaging

Obstetrics or Gynecology

Cardiology

Urology

Vascular

Orthopedic and Musculoskeletal

Pain Management

Others

### By End-User

Hospitals

Surgical Centers and Diagnostic Centers

Maternity Centers

Ambulatory Care Centers

Research and Academia

Others

## 4.3 Growth Prospects and Niche Opportunities, 2023- 2030

## 4.4 Regional comparison of Market Growth, CAGR, 2023-2030

## 5. REGION-WISE MARKET OUTLOOK TO 2030

### 5.1 Key Findings for Asia Pacific Neuroendocrine Tumors Therapeutics Market, 2025

### 5.2 Asia Pacific Neuroendocrine Tumors Therapeutics Market Size Outlook by Type, 2021- 2030

### 5.3 Asia Pacific Neuroendocrine Tumors Therapeutics Market Size Outlook by Application, 2021- 2030

### 5.4 Key Findings for Europe Neuroendocrine Tumors Therapeutics Market, 2025

### 5.5 Europe Neuroendocrine Tumors Therapeutics Market Size Outlook by Type, 2021-

2030

5.6 Europe Neuroendocrine Tumors Therapeutics Market Size Outlook by Application, 2021- 2030

5.7 Key Findings for North America Neuroendocrine Tumors Therapeutics Market, 2025

5.8 North America Neuroendocrine Tumors Therapeutics Market Size Outlook by Type, 2021- 2030

5.9 North America Neuroendocrine Tumors Therapeutics Market Size Outlook by Application, 2021- 2030

5.10 Key Findings for South America Neuroendocrine Tumors Therapeutics Market, 2025

5.11 South America Pacific Neuroendocrine Tumors Therapeutics Market Size Outlook by Type, 2021- 2030

5.12 South America Neuroendocrine Tumors Therapeutics Market Size Outlook by Application, 2021- 2030

5.13 Key Findings for Middle East and Africa Neuroendocrine Tumors Therapeutics Market, 2025

5.14 Middle East Africa Neuroendocrine Tumors Therapeutics Market Size Outlook by Type, 2021- 2030

5.15 Middle East Africa Neuroendocrine Tumors Therapeutics Market Size Outlook by Application, 2021- 2030

## **6. COUNTRY-WISE MARKET SIZE OUTLOOK TO 2030**

6.1 US Neuroendocrine Tumors Therapeutics Market Size Outlook and Revenue Growth Forecasts

6.2 US Neuroendocrine Tumors Therapeutics Industry Drivers and Opportunities

6.3 Canada Market Size Outlook and Revenue Growth Forecasts

6.4 Canada Neuroendocrine Tumors Therapeutics Industry Drivers and Opportunities

6.6 Mexico Market Size Outlook and Revenue Growth Forecasts

6.6 Mexico Neuroendocrine Tumors Therapeutics Industry Drivers and Opportunities

6.7 Germany Market Size Outlook and Revenue Growth Forecasts

6.8 Germany Neuroendocrine Tumors Therapeutics Industry Drivers and Opportunities

6.9 France Market Size Outlook and Revenue Growth Forecasts

6.10 France Neuroendocrine Tumors Therapeutics Industry Drivers and Opportunities

6.11 UK Market Size Outlook and Revenue Growth Forecasts

6.12 UK Neuroendocrine Tumors Therapeutics Industry Drivers and Opportunities

6.13 Spain Market Size Outlook and Revenue Growth Forecasts

6.14 Spain Neuroendocrine Tumors Therapeutics Industry Drivers and Opportunities

6.16 Italy Market Size Outlook and Revenue Growth Forecasts

- 6.16 Italy Neuroendocrine Tumors Therapeutics Industry Drivers and Opportunities
- 6.17 Rest of Europe Market Size Outlook and Revenue Growth Forecasts
- 6.18 Rest of Europe Neuroendocrine Tumors Therapeutics Industry Drivers and Opportunities
- 6.19 China Market Size Outlook and Revenue Growth Forecasts
- 6.20 China Neuroendocrine Tumors Therapeutics Industry Drivers and Opportunities
- 6.21 India Market Size Outlook and Revenue Growth Forecasts
- 6.22 India Neuroendocrine Tumors Therapeutics Industry Drivers and Opportunities
- 6.23 Japan Market Size Outlook and Revenue Growth Forecasts
- 6.24 Japan Neuroendocrine Tumors Therapeutics Industry Drivers and Opportunities
- 6.26 South Korea Market Size Outlook and Revenue Growth Forecasts
- 6.26 South Korea Neuroendocrine Tumors Therapeutics Industry Drivers and Opportunities
- 6.27 Australia Market Size Outlook and Revenue Growth Forecasts
- 6.28 Australia Neuroendocrine Tumors Therapeutics Industry Drivers and Opportunities
- 6.29 South East Asia Market Size Outlook and Revenue Growth Forecasts
- 6.30 South East Asia Neuroendocrine Tumors Therapeutics Industry Drivers and Opportunities
- 6.31 Rest of Asia Pacific Market Size Outlook and Revenue Growth Forecasts
- 6.32 Rest of Asia Pacific Neuroendocrine Tumors Therapeutics Industry Drivers and Opportunities
- 6.33 Brazil Market Size Outlook and Revenue Growth Forecasts
- 6.34 Brazil Neuroendocrine Tumors Therapeutics Industry Drivers and Opportunities
- 6.36 Argentina Market Size Outlook and Revenue Growth Forecasts
- 6.36 Argentina Neuroendocrine Tumors Therapeutics Industry Drivers and Opportunities
- 6.37 Rest of South America Market Size Outlook and Revenue Growth Forecasts
- 6.38 Rest of South America Neuroendocrine Tumors Therapeutics Industry Drivers and Opportunities
- 6.39 Middle East Market Size Outlook and Revenue Growth Forecasts
- 6.40 Middle East Neuroendocrine Tumors Therapeutics Industry Drivers and Opportunities
- 6.41 Africa Market Size Outlook and Revenue Growth Forecasts
- 6.42 Africa Neuroendocrine Tumors Therapeutics Industry Drivers and Opportunities

## **7. NEUROENDOCRINE TUMORS THERAPEUTICS MARKET OUTLOOK ACROSS SCENARIOS**

### 7.1 Low Growth Case

7.2 Reference Growth Case

7.3 High Growth Case

## **8. NEUROENDOCRINE TUMORS THERAPEUTICS COMPANY PROFILES**

8.1 Profiles of Leading Neuroendocrine Tumors Therapeutics Companies in the Market

8.2 Business Descriptions, SWOT Analysis, and Growth Strategies

8.3 Financial Performance and Key Metrics

AVEO Pharmaceuticals Inc

Boehringer Ingelheim International GmbH

Bristol-Myers Squibb

Eli Lilly & Company

F. Hoffmann-La Roche Ltd

Hutchison MediPharma Ltd

Ipsen

Jubilant Life Sciences Ltd

Lantheus Holdings Inc

Novartis AG

Pfizer Inc

Tarveda Therapeutics

## **9. APPENDIX**

9.1 Scope of the Report

9.2 Research Methodology and Data Sources

9.3 Glossary of Terms

9.4 Market Definitions

9.5 Contact Information

## I would like to order

Product name: Neuroendocrine Tumors Therapeutics Market Size, Trends, Analysis, and Outlook By Product (Somatostatin Analogs (SSAs), Targeted Therapy, Chemotherapy, Others), By Indication (Lungs, Pancreas, Gastrointestinal, Others), By End-User (Hospitals, Clinics, Others), by Region, Country, Segment, and Companies, 2024-2030

Product link: <https://marketpublishers.com/r/N6FBE1064A80EN.html>

Price: US\$ 3,980.00 (Single User License / Electronic Delivery)

If you want to order Corporate License or Hard Copy, please, contact our Customer Service:

[info@marketpublishers.com](mailto:info@marketpublishers.com)

## Payment

To pay by Credit Card (Visa, MasterCard, American Express, PayPal), please, click button on product page <https://marketpublishers.com/r/N6FBE1064A80EN.html>

To pay by Wire Transfer, please, fill in your contact details in the form below:

First name:  
Last name:  
Email:  
Company:  
Address:  
City:  
Zip code:  
Country:  
Tel:  
Fax:  
Your message:

**\*\*All fields are required**

Customer signature \_\_\_\_\_

Please, note that by ordering from marketpublishers.com you are agreeing to our Terms & Conditions at <https://marketpublishers.com/docs/terms.html>

To place an order via fax simply print this form, fill in the information below  
and fax the completed form to +44 20 7900 3970